These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 35908379)
1. Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab). Peiffer LB; White JR; Jones CB; Slottke RE; Ernst SE; Moran AE; Graff JN; Sfanos KS Neoplasia; 2022 Oct; 32():100822. PubMed ID: 35908379 [TBL] [Abstract][Full Text] [Related]
2. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555 [TBL] [Abstract][Full Text] [Related]
3. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Graff JN; Liang LW; Kim J; Stenzl A Future Oncol; 2021 Aug; 17(23):3017-3026. PubMed ID: 34044584 [TBL] [Abstract][Full Text] [Related]
4. Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer. Higa J; Wilenius K; Savino S; Larsen C; Scholz M; Vogelzang N Clin Genitourin Cancer; 2020 Aug; 18(4):e397-e401. PubMed ID: 31919032 [TBL] [Abstract][Full Text] [Related]
5. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695 [TBL] [Abstract][Full Text] [Related]
6. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Newsome RC; Gharaibeh RZ; Pierce CM; da Silva WV; Paul S; Hogue SR; Yu Q; Antonia S; Conejo-Garcia JR; Robinson LA; Jobin C Genome Med; 2022 Mar; 14(1):35. PubMed ID: 35346337 [TBL] [Abstract][Full Text] [Related]
7. A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. Payne H; Robinson A; Rappe B; Hilman S; De Giorgi U; Joniau S; Bordonaro R; Mallick S; Dourthe LM; Flores MM; Gumà J; Baron B; Duran A; Pranzo A; Serikoff A; Mott D; Herdman M; Pavesi M; De Santis M Int J Cancer; 2022 Mar; 150(5):837-846. PubMed ID: 34648657 [TBL] [Abstract][Full Text] [Related]
8. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan. Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973 [TBL] [Abstract][Full Text] [Related]
9. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer. van Nuland M; Bergman AM; Rosing H; de Vries N; Huitema ADR; Beijnen JH Pharmacotherapy; 2019 Dec; 39(12):1137-1145. PubMed ID: 31596947 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. Soleimani M; Zou K; Sunderland K; Struss W; Eigl BJ; Nappi L; Kollmannsberger CK; Finch D; Noonan K; Vergidis J; Zulfiqar M; Chi KN; Khalaf DJ Eur J Cancer; 2021 Jul; 152():215-222. PubMed ID: 34130153 [TBL] [Abstract][Full Text] [Related]
11. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722 [TBL] [Abstract][Full Text] [Related]
12. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID; BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967 [TBL] [Abstract][Full Text] [Related]
13. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Markowski MC; Shenderov E; Eisenberger MA; Kachhap S; Pardoll DM; Denmeade SR; Antonarakis ES Prostate; 2020 Apr; 80(5):407-411. PubMed ID: 31972048 [TBL] [Abstract][Full Text] [Related]
14. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Sfanos KS; Markowski MC; Peiffer LB; Ernst SE; White JR; Pienta KJ; Antonarakis ES; Ross AE Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):539-548. PubMed ID: 29988102 [TBL] [Abstract][Full Text] [Related]
15. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987 [TBL] [Abstract][Full Text] [Related]
16. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983 [TBL] [Abstract][Full Text] [Related]
17. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. Freedland SJ; Li S; Pilon D; Bhak RH; Narkhede S; Lefebvre P; Young-Xu Y Curr Med Res Opin; 2021 Apr; 37(4):635-642. PubMed ID: 33571020 [TBL] [Abstract][Full Text] [Related]
18. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Haas NB; LaRiviere MJ; Buckingham TH; Cherkas Y; Calara-Nielsen K; Foulk B; Patel J; Gross S; Smirnov D; Vaughn DJ; Amaravadi R; Wellen KE; Savitch SL; Majmundar KJ; Black TA; Yee SS; He M; Min EJ; Long Q; Jones JO; Pal SK; Carpenter EL Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):448-456. PubMed ID: 33009489 [TBL] [Abstract][Full Text] [Related]
19. Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel. Bilgetekin I; Basal FB; Cinkir HY; Esin E; Oksuzoglu B; Demirci U J Coll Physicians Surg Pak; 2020 Aug; 30(8):815-821. PubMed ID: 32893792 [TBL] [Abstract][Full Text] [Related]
20. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study. Pu YS; Ahn H; Han W; Huang SP; Wu HC; Ma L; Yamada S; Suga K; Xie LP Adv Ther; 2022 Jun; 39(6):2641-2656. PubMed ID: 35397772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]